Medicaid rebates for brand-name drugs exceeded Part D rebates by a substantial margin.
(eBook)
Description
Also in this Series
More Details
Notes
Citations
United States. Department of Health and Human Services. Office of Inspector General. (2015). Medicaid rebates for brand-name drugs exceeded Part D rebates by a substantial margin . Department of Health and Human Services, Office of Inspector General.
Chicago / Turabian - Author Date Citation, 17th Edition (style guide)United States. Department of Health and Human Services. Office of Inspector General. 2015. Medicaid Rebates for Brand-name Drugs Exceeded Part D Rebates By a Substantial Margin. Department of Health and Human Services, Office of Inspector General.
Chicago / Turabian - Humanities (Notes and Bibliography) Citation, 17th Edition (style guide)United States. Department of Health and Human Services. Office of Inspector General. Medicaid Rebates for Brand-name Drugs Exceeded Part D Rebates By a Substantial Margin Department of Health and Human Services, Office of Inspector General, 2015.
MLA Citation, 9th Edition (style guide)United States. Department of Health and Human Services. Office of Inspector General. Medicaid Rebates for Brand-name Drugs Exceeded Part D Rebates By a Substantial Margin Department of Health and Human Services, Office of Inspector General, 2015.
Staff View
Grouping Information
| Grouped Work ID | 3bcd22f3-7c99-00d6-a0c9-5757c644bcad-eng |
|---|---|
| Full title | medicaid rebates for brand name drugs exceeded part d rebates by a substantial margin |
| Author | united states department of health and human servi |
| Grouping Category | book |
| Last Update | 2023-05-05 15:45:20PM |
| Last Indexed | 2024-07-06 23:23:27PM |
Book Cover Information
| Image Source | default |
|---|---|
| First Loaded | Jan 9, 2023 |
| Last Used | Dec 14, 2023 |
Marc Record
| First Detected | Jun 01, 2016 12:00:00 AM |
|---|---|
| Last File Modification Time | May 05, 2023 03:51:51 PM |
MARC Record
| LEADER | 01725cam a2200433 i 4500 | ||
|---|---|---|---|
| 001 | ocn950968856 | ||
| 003 | OCoLC | ||
| 005 | 20160601090702.0 | ||
| 006 | m o d f | ||
| 007 | cr m|||||||||| | ||
| 008 | 160601s2015 dcua ob f000 0 eng c | ||
| 040 | |a GPO|b eng|e rda|e pn|c GPO|d MvI | ||
| 042 | |a pcc | ||
| 043 | |a n-us--- | ||
| 074 | |a 0445-B-07 (online) | ||
| 086 | 0 | |a HE 1.75:OEI-03-13-00650 | |
| 088 | |a OEI-03-13-00650 | ||
| 099 | |a HE 1.75:OEI-03-13-00650 | ||
| 110 | 1 | |a United States.|b Department of Health and Human Services.|b Office of Inspector General,|e author. | |
| 245 | 1 | 0 | |a Medicaid rebates for brand-name drugs exceeded Part D rebates by a substantial margin. |
| 246 | 1 | |i Running title:|a Medicaid rebates for brand-name drugs exceeded Part D rebates by a substantial margin | |
| 264 | 1 | |a [Washington, D.C.] :|b Department of Health and Human Services, Office of Inspector General,|c 2015. | |
| 300 | |a 1 online resource (12 pages) :|b color illustrations | ||
| 336 | |a text|2 rdacontent | ||
| 337 | |a computer|2 rdamedia | ||
| 338 | |a online resource|2 rdacarrier | ||
| 500 | |a Title from title screen (viewed May 31, 2016). | ||
| 500 | |a "April 2015." | ||
| 500 | |a "OEI-03-13-00650." | ||
| 500 | |a GPO Cataloging Record Distribution Program (CRDP). | ||
| 504 | |a Includes bibliographical references. | ||
| 610 | 1 | 0 | |a United States.|t Patient Protection and Affordable Care Act. |
| 650 | 0 | |a Medicare|x Finance. | |
| 650 | 0 | |a Medicaid|x Finance. | |
| 650 | 0 | |a Drugs|x Finance|x Government policy|z United States. | |
| 650 | 0 | |a Brand name products|z United States|x Costs. | |
| 650 | 0 | |a Rebates|z United States. | |
| 856 | 4 | 0 | |u https://purl.fdlp.gov/GPO/gpo68613 |
| 949 | |a HE 1.75:OEI-03-13-00650|t x | ||